

**Development of WHO Guidelines for the Prevention of
Mother-to-Child Transmission of Hepatitis B Virus Infection**

**Guidelines Development Group Meeting
9 – 10 September 2019
Room - D46025 (4th Floor, D Building)
Geneva, Switzerland**

PROPOSED AGENDA

DAY 1: 9 SEPTEMBER 2019		
TIME	AGENDA ITEM	SPEAKERS/FACILITATORS
8:30 – 9:00	Registration	All
Setting the scene Chair: Anita Suleiman, <i>Ministry of Health Malaysia</i>		
9:00 - 11:00	Welcome remarks	HIV Director, WHO
	Introductions <ul style="list-style-type: none">• Declarations of Interest	Global Hepatitis Team Leader, WHO
	Meeting overview <ul style="list-style-type: none">• Objectives, expected outcomes, and working methods• Overview of hepatitis guidelines activities	Global Hepatitis Team Leader, WHO
	What is GRADE? <ul style="list-style-type: none">• Overview of GRADE methodology and decision making tables• Discussion	Roger Chou Oregon Health & Science University
	<ul style="list-style-type: none">• Role of HBV PMTCT in viral hepatitis elimination	TBC
11:00 - 11:30	Tea/Coffee Break	
PICO 1: Review of evidence Chair: Anita Suleiman		
11:30 - 12:30	Efficacy and safety of antiviral therapy during pregnancy for HBV PMTCT: systematic review and meta analyses.	Yusuke Shimakawa, Institut Pasteur

DAY 1: 9 SEPTEMBER 2019 (continued)		
12:30 – 13:30	Lunch Break	
Review of evidence (continued)		
Chair: Anita Suleiman		
13:30 - 15:30	Modelling impact of HBV peripartum antiviral therapy	
	Overview of evidence (modelling) Questions	Shevanthy Nayagam, Imperial College
	Modelling the cost-effectiveness of HBV peripartum antiviral therapy	
	Overview of evidence (modelling) Questions	Shevanthy Nayagam, ImperialCollege
	Presentation of feasibility survey Questions	TBC
15:30 - 16:00	Tea/Coffee Break	
Development of Recommendations		
Chair: Anita Suleiman		
16:00 - 17:30	PICO 1: Efficacy and safety of antiviral therapy during pregnancy for HBV PMTCT	
	PICO 1: Discussion on evidence, decision making table and development of recommendations	
	Wrap up	
17:30 - 19:00	Guidelines group photo, followed by drinks, Red Ribbon Cafeteria	
DAY 2: 10 SEPTEMBER 2019		
TIME	AGENDA ITEM	SPEAKERS/FACILITATORS
9:00 - 9:15	Overview of day 1 and Agenda for day 2	Global Hepatitis Team Leader, WHO
Review of the evidence		
Chair: Anita Suleiman		
9:15 - 10:30	PICO 2: Can HbeAg tests be used as an alternative to HBV DNA tests to assess HBV treatment eligibility to prevent mother-to-child transmission in pregnant women?	
	Performance of hepatitis B e antigen (HBeAg) test, as an alternative to HBV DNA, to assess eligibility for initiating antiviral therapy during pregnancy to prevent mother-to-child transmission of hepatitis B: A systematic review and meta-analysis	Yusuke Shimakawa Institut Pasteur
	Presentation of feasibility survey	TBC

10:30 - 11:00	Tea/Coffee Break	
Development of Recommendations Chair: Anita Suleiman		
11:00 - 12:30	PICO 2: Use of HbeAg tests as an alternative to HBV DNA to assess eligibility for initiating antiviral therapy during pregnancy to prevent mother-to-child transmission of hepatitis B.	
	PICO 2: Discussion on evidence, decision making table, and development of recommendations	
12:30 - 13:30	Lunch break	
Development of Recommendations (continued) Chair: Anita Suleiman		
13:30 - 15:00	Review of PICO 1 and PICO 2 recommendations	
	<ul style="list-style-type: none">Develop consensus on and rank the strength of the final recommendationsFinalizing the recommendations	Roger Chou Oregon health & science university
15:00 - 15:30	Tea/Coffee Break	
Overview Chair: Anita Suleiman		
15:30 - 16:30	<ul style="list-style-type: none">Introduction of Next stepsNeed for additional data or analysisProduction timelinePeer review process	
	Wrap up	
16:30 - 17:00	Meeting Close	